Expert Discusses CAR T-Cell Advances in ALL – OncLive
OncLive |
Expert Discusses CAR T-Cell Advances in ALL
OncLive Data from the phase II ELIANA study presented at the 2016 ASH Annual Meeting showed that the CAR T-cell therapy CTL019 induced an 83% complete remission (CR) or CR with incomplete blood count recovery (CRi) rate in pediatric and young adult … |
